KRAS and invasive ductal breast carcinoma: They also showed that deltarasin inhibits the interaction between KRAS–PDEδ and decreases KRAS binding to the PM in human ductal adenocarcinoma (PDAC) cell lines harboring KRAS gene mutation, resulting in reduction of cell proliferation and induction of apoptosis both in vitro and in vivo.